Transition Therapeutics Acquires Exclusive License to GLP-1 for Type I Diabetes Patent Portfolio
Advertisement
Transition Therapeutics Inc. announced the signing of an exclusive license agreement to a patent portfolio for the use of Glucagon-Like Peptide-1 ("GLP-1") analogues in the treatment of Type I diabetes. The Patent Portfolio includes two issued US patents (US No. 6,989,148 & US No. 6,899,883). The claims in these issued US patents cover the use of GLP-1 analogues alone or in combination with insulins for the treatment of Type I diabetes.
The addition of this patent portfolio strengthens the overall intellectual property protection of Transition's GLP1-I.N.T.(TM) regenerative product. The license also provides Transition with exclusivity to key claims necessary for GLP-1 analogue therapy to extend to Type I diabetes in the United States.
Transition signed this exclusive license agreement to the Patent Portfolio with London Health Sciences Centre Research Inc. ("LHSCRI"). Under the terms of the Agreement, Transition will issue to LHSCRI a number of Transition common shares having a value of $286,000 at a price equal to the weighted average trading price of Transition shares from March 15 - March 21, 2006. In addition, LHSCRI is entitled to receive milestone payments and royalties on amounts actually received by Transition from the net sales of products covered by issued Patent Portfolio claims or the sublicense of the Patent Portfolio.
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents
Currently positioned only 5th, China is the fastest growing biotech market in the world
Pharmexa adds two strong new members to board of directors
Antisense Pharma Granted Patents on Medical Device for Application of Neurotherapeutics
Molecular Profiles Invests £9 million in New Facility To Increase Manufacturing Capabilities for Phase I and II Clinical Trials
EyeTechCare raises EUR 7.5 million in a second funding round and speeds up its development
David Evans steps down as chairman of the board for Horizon Discovery
New clinical and preclinical data on Basilea's novel antibiotic BAL30072 against multidrug-resistant Gram-negative superbugs